Three Months Ended June 30,

Six Months Ended June 30,

2020

2019

2020

2019

Basic

Net income (loss) attributable to American Renal Associates Holdings, Inc.

$

795

$

(8,178)

$

(6,439)

$

(18,657)

Change in the difference between the redemption value and estimated fair value for accounting purposes of the related noncontrolling interests

(444)

1,025

(703)

284

Net income (loss) attributable to common shareholders

$

351

$

(7,153)

$

(7,142)

$

(18,373)

Weighted-average common shares outstanding

32,862,637

32,275,807

32,661,238

32,232,004

Earnings (loss) per share, basic

$

0.01

$

(0.22)

$

(0.22)

$

(0.57)

Diluted

Net income (loss) attributable to American Renal Associates Holdings, Inc.

$

795

$

(8,178)

$

(6,439)

$

(18,657)

Change in the difference between the redemption value and estimated fair value for accounting purposes of the related noncontrolling interests

(444)

1,025

(703)

284

Net income (loss) attributable to common shareholders for diluted earnings per share calculation

$

351

$

(7,153)

$

(7,142)

$

(18,373)

Weighted-average common shares outstanding, basic

32,862,637

32,275,807

32,661,238

32,232,004

Weighted-average common shares outstanding, assuming dilution

34,612,591

32,275,807

32,661,238

32,232,004

Earnings (loss) per share, diluted

$

0.01

$

(0.22)

$

(0.22)

$

(0.57)

Outstanding options and restricted stock excluded as impact would be anti-dilutive

2,427,031

3,235,582

2,948,016

3,404,444